Reimagining Medicine
Company overview
Innovation: Pipeline overview
Cardiovascular
NIS793 - TGFẞ inhibitor
Financial review
Immunology
NCT04935359 daNIS-2 (CNIS793B12301)
Indication
Phase
1L metastatic pancreatic ductal Adenocarcinoma
Phase 3
Patients
501
Primary
Outcome
Measures
Arms
Intervention
2023 priorities
Innovation: Clinical trials
Neuroscience
Safety run-in part: Percentage of participants with dose limiting toxicities
(DLTs) during the first cycle (4 weeks) of treatment
Randomized part: Overall survival (OS)
Safety run-in part: NIS793+gemcitabine+nab-paclitaxel
Randomized portion of the study:
Arm 1: NIS793+gemcitabine+nab-paclitaxel
Arm 2: placebo+gemcitabine+nab-paclitaxel
Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), first
line treatment
Primary: 2024
Target
Patients
Readout
Milestone(s)
Publication
NA
88 Investor Relations | Q4 2022 Results
Oncology
Appendix
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation